The risk of hair loss in patients taking GLP-1 drugs, while low, is higher than with other diabetes drugs, new studies suggest.

Has a wanted fugitive been posing as a biotech executive? And what does it take to develop a therapy for an ultra-rare ...

Eli Lilly will seek regulatory approval for retatrutide, a powerful weight loss drug that a new study shows helped people lose nearly 56 pounds on average.

Lilly's purchase of AtaiBeckley is yet another strategic move in its bid to diversify its pipeline.

Eli Lilly and Co. LLY on Thursday reported topline results from two pivotal Phase 3 trials for its investigational ...

Eli Lilly & Co.’s highly anticipated next-generation weight-loss shot didn’t increase overall heart risk in a new study, the ...

Eli Lilly is preparing application materials for its next-generation weight-loss drug, retatrutide, following data from two ...

The new findings position Lilly to file an application for the highly anticipated medicine, but also leave some questions about the additive benefits a “triple-G” drug has on heart health.

A $2.5 billion settlement with Amazon Prime is in the works, a pharmaceutical company accuses another of false advertising ...

There are now positive results from five late-stage trials on retatrutide, which Lilly is positioning as the next pillar of ...

Elaine’s stories explore the boom in new obesity treatments, new drug payment models, the ways companies are affected by FDA changes, and the emerging psychedelics drug sector. She co-writes The ...

Comcast reported a lower profit in the second quarter, but narrowed subscriber losses in its domestic residential-broadband business for the second quarter in a row. Lockheed Martin Raises Full-Year ...